# OXYGENTA PHARMA (NSE: OXYGENTAPH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/OXYGENTAPH · Pivot · prices to 21 Oct 2026

With a market capitalisation of ₹185 Cr, it ranks 2321st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 0.0% in FY25. Promoters held 56.54% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹185 Cr |
| ROE | 0.0% (FY25) |
| ROCE | 391.4% (FY25) |
| Debt to equity | -2.49 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹109 Cr | −₹10 Cr |
| FY24 | ₹40 Cr | −₹3 Cr |
| FY23 | ₹31 Cr | −₹12 Cr |
| FY22 | ₹61 Cr | −₹1 Cr |
| FY21 | ₹52 Cr | ₹3 Cr |
| FY20 | ₹14 Cr | −₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 56.54%
- Domestic institutions: 0.03%
- Non-institutions: 43.44%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Coral Labs](https://app.pivotnow.in/stock/CORALAB) | — | ₹196 Cr | — | — |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | — | — |
| [Accretion Nutra](https://app.pivotnow.in/stock/ANL) | — | ₹184 Cr | — | — |
| [Brooks Laboratories](https://app.pivotnow.in/stock/BROOKS) | ₹61.79 | ₹182 Cr | 7.4 | — |
| [Earkart](https://app.pivotnow.in/stock/EARKART) | — | ₹182 Cr | — | — |
| [Novelix Pharma](https://app.pivotnow.in/stock/NOVELIX) | — | ₹181 Cr | — | — |

## Questions and answers

### What is the market cap of OXYGENTA PHARMA?

OXYGENTA PHARMA's market capitalisation is ₹185 Cr (₹185 Cr) at the 21 Oct 2026 close, ranking 2321st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of OXYGENTA PHARMA?

Return on equity was 0.0% in FY25 and return on capital employed was 391.4% in FY25 (standalone figures).

### Is OXYGENTA PHARMA a debt-free company?

OXYGENTA PHARMA is close to debt-free: its debt-to-equity ratio was -2.49 in FY25.

### What is the shareholding pattern of OXYGENTA PHARMA?

As of 30 Jun 2026: promoters 56.54%, domestic institutions 0.03%, non-institutions 43.44%.

### Who are OXYGENTA PHARMA's competitors?

The listed Pharma & Healthcare companies closest to OXYGENTA PHARMA by market cap are Coral Labs, Aashka Hospital, Accretion Nutra, Brooks Laboratories, Earkart and Novelix Pharma.

### Is OXYGENTA PHARMA a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out OXYGENTA PHARMA's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on OXYGENTAPH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.